Late Functional Outcomes After Robot-Assisted Radical Prostatectomy: Impact of Baseline and Perioperative Risk Factors
Cancers · 29.04.2026 · 18 (9) · 1406
DOI: 10.3390/cancers18091406 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 29.04.2026. Verfasst von Hanka Princlova und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Hradec Kralove, 50005 Hradec Kralove, Czech Republic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charles University in Prague COOPERATIO Program.
Abstract (Originalsprache)
Introduction
Late functional outcomes remain major determinants of quality of life after robot-assisted radical prostatectomy (RARP). Although several baseline and perioperative factors have been linked to postoperative stress urinary incontinence (SUI) and erectile dysfunction (ED), their cumulative effect remains incompletely characterized in large real-world cohorts. Materials and Methods: This retrospective single-center study included 862 consecutive patients undergoing RARP for localized prostate cancer. All endpoints were assessed at a fixed 12-month follow-up visit; therefore, a median follow-up beyond this predefined time point was not applicable. Outcomes were derived from patient-reported information documented during routine follow-up and comprised pad use, ED, and urethral anastomotic stricture. Age, body mass index (BMI), console time, estimated blood loss, and prostate weight were selected a priori based on clinical relevance and uniform availability and were analyzed using univariable and multivariable logistic regression. A simple exploratory composite risk score (0–5 points) was constructed by assigning one point for each predefined adverse factor.
Results
At 12 months, 50.0% of patients were pad-free, 85.6% achieved social continence (0–1 pad/day), 14.5% had clinically significant incontinence (>1 pad/day), 71.5% had chart-documented ED, and 1.0% developed urethral anastomotic stricture. In multivariable analysis, age (OR 1.039, 95% CI 1.018–1.059) and prostate weight (OR 1.011, 95% CI 1.004–1.018) independently predicted SUI, while age was the only independent predictor of ED (OR 1.029, 95% CI 1.007–1.050). No predictor of stricture was identified. The composite score showed an exploratory dose–response association with SUI (OR 1.364 per point, 95% CI 1.208–1.541; AUC 0.597) and a weaker association with ED (OR 1.149, 95% CI 1.007–1.313; AUC 0.540).
Conclusions
A simple composite score may provide pragmatic exploratory grouping of SUI risk after RARP, but discrimination is modest and interpretation is limited by non-validated outcome assessment and the absence of major confounders, including nerve-sparing status and baseline functional measures.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, University Hospital Hradec Kralove, 50005 Hradec Kralove, Czech Republic.
- Faculty of Medicine in Hradec Kralove, Charles University, 50005 Hradec Kralove, Czech Republic.
ORCID-Profile: Pavel Navratil
Förderung
- Charles University in Prague COOPERATIO Program
Zitieren
APA
Princlova, H., Izmaylov, O., Tranova, M. N., & Navratil, P. (2026). Late Functional Outcomes After Robot-Assisted Radical Prostatectomy: Impact of Baseline and Perioperative Risk Factors. Cancers, 18(9), 1406. https://doi.org/10.3390/cancers18091406
Vancouver
Princlova H, Izmaylov O, Tranova MN, Navratil P. Late Functional Outcomes After Robot-Assisted Radical Prostatectomy: Impact of Baseline and Perioperative Risk Factors. Cancers. 2026;18(9):1406. doi:10.3390/cancers18091406
BibTeX
@article{Princlova2026,
author = {Princlova, Hanka and Izmaylov, Oleg and Tranova, Minh Nguyet and Navratil, Pavel},
title = {Late Functional Outcomes After Robot-Assisted Radical Prostatectomy: Impact of Baseline and Perioperative Risk Factors},
journal = {Cancers},
year = {2026},
volume = {18},
number = {9},
pages = {1406},
doi = {10.3390/cancers18091406}
}
EUVIMED